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ABSTRACT
Polymeric film-forming solutions (FFSs) are novel and emerging drug delivery
systems for topical application to the skin. In their simplest composition, they constitute an
active drug substance, film-forming polymer, and a volatile skin-tolerant solvent. When applied
to the skin, FFSs form a thin and transparent polymeric film shortly after solvent evaporation.
Owing to their unique composition and formation mechanism, these systems offer many superior
advantages to the more conventional topical dosage forms. Thereby, this work aimed to develop
and characterize film forming solutions for the skin delivery of two of the most commonly used
topical non-steroidal anti-inflammatory drugs (NSAIDS); ketoprofen and diclofenac sodium.
FFS were developed by varying the type and content of the film forming polymer. The
resulting formulations were evaluated according to favorable film characteristics, in vitro and ex
vivo drug release profiles. Eudragit E100 was identified as a suitable release matrix for
ketoprofen. In the case of diclofenac Na; however, the ex vivo permeation study results failed to
show a characteristic release profile for either the test formulation or the marketed formulation
VOLTAREN® Gel.
Nevertheless, the presented work provided a rationalized way for the development and
evaluation of FFS and investigated their potential as delivery systems for ketoprofen and
diclofenac sodium.
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CHAPTER I
INTRODUCTION
In situ film forming polymeric solution is a novel and emerging approach for dermal and
transdermal drug delivery. These solutions in their simplest composition comprise a drug
substance, a film-forming polymer, and a skin-tolerant volatile solvent1. They are applied on the
skin as liquids forming a very thin polymeric film after the rapid evaporation of the solvent. The
formed films provide superior advantages over the more conventional topical dosage forms; they
are flexible, fast-drying, less greasy and do not carry the risk of being wiped off the skin compared
to semisolid formulations. Above all, the most crucial attribute of in situ film forming solutions is
the complete skin contact over the entire application period without causing any skin fixation or
irritation as in the case of topical patches. This potential advantage is especially essential for the
management of chronic skin diseases where the repetitive application is a major cause of poor
patient compliance and satisfaction as well as poor therapeutic outcomes.
Based on this rational, two of the most prescribed topical non-steroidal anti-inflammatory
drugs (NSAIDS); ketoprofen and diclofenac Na were formulated as polymeric film-forming
solutions for skin delivery. Table 1 represents some of the physical and chemical properties of
diclofenac Na and ketoprofen2,3.
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Table 1: Some of ketoprofen and diclofenac Na physical and chemical properties
Property

Ketoprofen

Diclofenac Na

Molecular weight

254.28 g/mol

296.14 g/mol

Melting point

94° C

283° C

Octanol/water partioning

3.12

4.51

Dissociation coefficient

4.45

4.15

Aqueous solubility

51 mg/L

2.37 mg/L

coefficient

Accordingly, the presented work aimed to develop FFS formulations of ketoprofen and
diclofenac Na using different types and concentrations of film-forming polymers and to
characterize and optimize the resulting formulations according to favorable film characteristics,
in vitro and ex vivo drug release profiles.
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CHAPTER II
OBJECTIVE OF THE STUDY
The objective of the present work was to develop, characterize and optimize FFSs for the
topical delivery of ketoprofen and diclofenac Na.
Research Strategy: The study was divided into two parts; the former was focused on the
formulation of different polymeric FFS formulations by varying the type and content of the
polymer. A selection of 13 polymers from different chemical groups, all described by their
manufacturer or in the literature as being film formers, were tested and evaluated for their film
characteristic and drug loading capacities. In the second part, we determined the in vitro, and ex
vivo release profiles of the formulations that passed the first stage of testing. All formulations were
made in two batches and were subjected to stability conditions for three months. Formulations
were kept at two conditions, 25ᵒC/60% RH and 40ᵒC/75% RH respectively.
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CHAPTER III
MATERIALS AND METHODS
Materials
Ketoprofen was purchased from Tokyo Chemical Industry Co., Ltd. Diclofenac sodium
salt, Chitosan and Poly( acrylic acid) were purchased from Sigma -Aldrich. Eudragit E100®
(dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate), Eudragit
EPO® (dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate),
Eudragit RLPO® (Methacrylic acid methylacrylate copolymer), and Eudragit RS100® were
purchased from Evonik Industries. Kollidon® 30 (Polyvinylpyrrolidone), Kollidon 90F®,
Kollidon SR, Soluplus® ( polyethylene glycol, polyvinyl acetate, and polyvinylcaprolactamebased graft copolymer) and Luterol® (Plyoxyl propylene-polyoxyethylene block copolymer)
were purchased from BASF. Carbopol was purchased from Lubrizol Corporation. Menthol was
purchased from Ward’s Natural Science. High-Performance Liquid Chromatography (HPLC)grade solvents like methanol, ethanol were purchased from Fisher Chemicals, USA. Porcine skin
was obtained from Pontotoc Slaughterhouse, Pontotoc, MS, USA. Dermatomed human cadaver
skin was purchased from New York Firefighters Skin Bank.
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Methods
Polymer screening
A selection of 13 polymers from different chemical classes were evaluated for their
solubility in 95% ethanol and the resulting film characteristics. The screened polymers herein
were all described by their manufacturer or in the literature as being film formers. Table 2
represents all the polymers that were used in this experiment.
Table 2: Polymers used in the screening experiment
Trade name

Polymer

Eudragit E 100

Poly(butyl

methacrylate,

(2-

dimethylaminoethyl)methacrylate,

methyl

methacrylate) 1:2:1
Eudragit RLPO

Ammonio methacrylate copolymer type A

Eudragit EPO

Butyl methylacrylate-(2-Dimethylaminoethyl)
methacrylate-Methyl methacrylate-copolymer

Kollidon 30

Polyvinylpyrrolidone

Kollidon 90F

Polyvinylpyrrolidone higher molecular weight

Kollidon SR

A blend of polyvinyl acetate and povidone (K
30) in the ratio 8:2

PVA 7200

Polyvinyl alcohol

5

Poly(acrylic acid)

Polyacrylic acid

Luterol®

Plyoxyl

propylene-polyoxyethylene

block

copolymer

Eudragit RS 100

Ammonio Methacrylate copolymer type B

Carbopol

Acrylic acid and C10-C30 alkyl acrylate
crosslinked with allyl pentaerythritol

Soluplus

Polyethylene glycol, polyvinyl acetate and
polyvinylcaprolactame-based graft copolymer

Chitosan

Polysaccharide

composed

of

randomly

distributed β--linked D-glucosamine and Nacetyl-D-glucosamine

Preparation of polymeric film forming solutions
The polymer was dissolved in 95% ethanol kept on stirring overnight until a clear solution
was obtained. The volume was made up to compensate the solvent lost due to evaporation.
Subsequently, the formulations were kept in glass vials sealed tightly with Parafilm®. Three
different concentrations were prepared for each of the screened polymers; 1%, 2.5% and 5% w/w.
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In vitro evaluation of the polymeric film forming solutions
The prepared polymeric solutions were initially evaluated according to the following
characteristics: solution appearance, solution viscosity, film drying time, outward stickiness and
cosmetic attractiveness of the produced films.
The appearance of the solutions was evaluated visually and described as clear or opaque
with or without precipitation of the polymer4. Likewise, the viscosity of the polymeric
formulations was visually assessed and rated as low (water-like), medium (glycerol-like) or high
(syrup-like)5.
For the evaluation of film drying time, the films were formed in small weighing boats.
After five minutes a glass slide was placed gently on the surface of the film. If no liquid droplets
are visible on the glass after removing it, the film was considered to be dry. If liquid droplets were
still visible on the slide, the test was repeated at seven minutes6.
Additionally, the outward stickiness of the films was estimated by pressing cotton wool on
the dry film with minimum pressure. Stickiness was rated high if heavy amount of fibers were
retained on the surface of the film, medium if a thin layer of fibers was formed on the film and low
if no adherence of fibers was noted5.
Moreover, the cosmetic appearance of the films was assessed. Complete, uniform and
transparent films were rated high in cosmetic attractiveness. While incomplete, non-uniform
and/or visible films were considered to be less attractive.
Formulations were considered successful when solutions were clear and of low viscosity.
And when the formed films had a drying time of ≤ 7 minutes, rated low on outward stickiness and
high in cosmetic attractiveness.
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Preparation of drug-loaded formulations
Fourteen FFS formulations passed the in vitro evaluation experiments and were loaded
with ketoprofen and diclofenac sodium. Table 3 shows the content of such formulations.

Table 3: Composition of drug loaded FFSs.
Drug levels (w/w%)
Polymer

1%

1.5%

(w/w%)
Kollidon 30

3%

5%

10%

Amount of the drug added (mg)
41

62

125.5

213.5

451

42.5

64

129

220

463

62

125.5

213.5

451

64

129

220

463

41

62

125.5

213.5

451

42.5

64

129

220

463

41

62

125.5

213.5

451

(2.5%)
Kollidon 30
(5%)
Kollidon 90F 41
(2.5%)
Kollidon 90F 42.5
(5%)
Kollidon SR
(2.5%)
Kollidon SR
(5%)
Eudragit
E100 (2.5%)
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Eudragit

42.5

64

129

220

463

41

62

125.5

213.5

451

42.5

64

129

220

463

41

62

125.5

213.5

451

42.5

64

129

220

463

41

62

125.5

213.5

451

42.5

64

129

220

463

E100 (5%)
Eudragit
RLPO
(2.5%)
Eudragit
RLPO (5%)
Eudragit
EPO (2.5%)
Eudragit
EPO (5%)
Soluplus
(2.5%)
Soluplus
(5%)

For the preparation of drug loaded FFS formulations, the polymers were first added to 95%
ethanol kept on stirrer overnight until completely dissolved. To the obtained clear solutions,
different amounts of ketoprofen and diclofenac sodium were added as shown in table 4. The
formulations were kept in glass vials sealed tightly with parafilm.
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Compound light microscopy
Crystallization of the drugs from the polymeric film forming solutions was evaluated with
compound light microscopy equipped with 10x, 20x, and 40x objectives. 100 µl of each of the
formulations was casted on a glass slide and allowed to dry at room temperature. The presence or
absence of drug’s crystals and their distribution was investigated at four different time points; 15
minutes, 1 hour, 2 hours and one day.
Film evaluation on pig skin
The formulations with the higher drug concentration that didn’t show any signs of drug’s
crystallization at any time point were considered successful were further assessed using pig skin.
Fresh porcine skin was brought from a local slaughterhouse. The abdominal skin regions were
taken and shaved using an electric shaver. The hairless skin was cut into small pieces. The skin
was mounted on a solid surface and used for film forming solution evaluation.
The drying time, outward stickiness and cosmetic attractiveness were evaluated as
mentioned above. Film flexibility was assessed by stretching the skin in 2-3 directions. The film
was rated flexible if no signs of cracking or skin fixation were observed or non-flexible if cracking
or skin fixation occurred1.
Formulations that showed short drying time, low outward stickiness, high cosmetical
attractiveness, and excellent flexibility were considered successful and were evaluated in the in
vitro drug release study.

In vitro drug release study
Determination of the transport of the drug across cellulose dialysis membrane was
performed using vertical Franz diffusion cells. The cells had receiver volume and diffusional
10

surface area of 5 ml and 0.64 cm² respectively. Dialysis membranes were cut into small pieces to
fit and were mounted on each diffusion cell. The donor and receiver chambers were clamped and
sealed with Parafilm®. The receiver fluid, Phosphate buffer saline (PBS) pH 7.4 was added and
any air bubbles trapped next to the membrane were removed initially and after each sampling
point. Small magnetic stirbars were added to the receiver chamber, and the temperature was
maintained at 32 °C by a circulating water jacket. To evaluate drug transport, 10 µl/cm² of each
formulation was added to the donor chamber.
Table 4 shows the composition of the formulations that were tested at this stage. Samples
of 200 µl of receiver fluid were removed at 0, 1, 2, 3, 4, 5, 6, 12 and 24 h. Following removal of
each sample, the same volume of fresh PBS was added to the receiver compartment to maintain
sink conditions. Samples were analyzed by HPLC.
Table 4: Composition of FFSs used in the In vitro release study
Formulation

A

B

C

D

Code
Polymer%

Kollidon 30

Kollidon 90F

Eudragit E100

Kollidon 90F

(w/w)

5%

5%

5%

2.5%

Drug % w/w

Diclofenac

Ketoprofen

Ketoprofen

3%

3%

3%

92%

92%

94.5%

3%
95%

ethanol 92%

Na Diclofenac Na

%w/w
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Ex vivo permeation study
Dermatomed human cadaver skin was obtained from New York Firefighters skin Bank
(525 E. 68th St. New York, NY 100065 USA). The skin was kept at -20 °C and slowly thawed
before use. The skin was rinsed with water and cut into pieces sufficient enough to cover the 0.64
cm2 diffusion area of the Franz cells. The skin was then fixed between the absorption and the
diffusion compartments of the cells, with the epidermis facing the receiver compartment. 10-15
µl/cm2 of the formulations were applied on the skin. After applying the formulations, 5 ml PBS
was immediately added to diffusion cells. Incubation temperature was maintained at 32 C, and
magnetic stirring rate was 600 rpm. Samples were withdrawn at 1, 2, 3, 4, 5, 6, 12 and 24 h, filtered
and replaced with 5 ml pre-heated fresh PBS at each time point. Drug concentration was
determined by HPLC.
Quantification of the drug within skin layers
Skin samples were removed carefully from the diffusion apparatus, and the exact diffusion
area was identified and punched out using a biopsy punch. Each skin disc then was rinsed using
5ml of a rinsing solvent (1ml at a time), and the resulting solutions were collected in glass vials.
The dried pre-weighted skin discs were immersed in NaOH (1M); the mixture was placed on a
stirrer for 24h. Subsequently, the extraction mixture was then centrifugated at 1300 rpm for 15min;
the supernatant fluid was then collected and analyzed by HPLC.

Stability Studies
Film forming solutions that passed the pig skin testing was kept for stability studies. The
samples were kept at conditions of 25ᵒC/60% RH and 40ᵒC/75% RH for three months in stability
chambers. The samples were withdrawn and analyzed for initial and three months. The
12

formulations were evaluated visually for any physical changes in solution appearance and color.
And drug content in the FFS was analyzed using UV-vis spectrophotometry. Absorbances of
diclofenac sodium samples were read spectrophotometrically at 275 nm, and for ketoprofen
samples at 254 nm taking ethanol as blank for both. All measurements were carried out at ambient
temperature, in a quartz cuvette of 1.00 cm optical length.
HPLC Analysis
The samples from in vitro release study and the ex vivo permeation study were analyzed
for their drug content by HPLC. An isocratic HPLC method was developed for the quantification
of ketoprofen and diclofenac sodium. The experiment was performed using a Waters HPLC system
(Water 600 Controller, USA) equipped with a 600-pump unit, a 717 plus autosampler with an
injection valve with a sample loop of 50 µl, and a 2487 dual absorbance UV detector.
Diclofenac sodium method: reversed phase Luna® 100° A C18 column (100x4.6 mm,
3µm, Phenomenex Inc, CA the USA) was utilized at ambient temperature. The mobile phase was
acetonitrile/water (3:1) adjusted to pH 3 with glacial acetic acid. The flow rate was set at 0.65
ml/min. Diclofenac sodium was detected at a wavelength of 275 nm with a retention time of 3.5.
20 µl of the injection was eluted in the column. The calibration curve was prepared using different
concentrations of diclofenac sodium in the range of 1µg to 10ng using methanol as a solvent. LOD,
LOQ were determined.
Ketoprofen method: A method stated in USP-NF was used. Phenomenex Luna® C18
reverse phase column (100 Å, 250 × 4.6 mm, 5 µm) was used as the solid phase. The mobile phase
was water, acetonitrile, and glacial acetic acid in the following ratio (90:110:1). The flow rate was
set at 1.2 mL/min. Ketoprofen was detected at 256 nm (Waters 2489 UV/detector) with a retention
time of approximately 4.7. Twenty microliters was injected from each sample. A ten point
13

calibration curve was plotted and found to be linear in the concentration range of 2 μg/mL to 100
μg/mL with a correlation coefficient (R2) of 0.999. The limit of detection and limit of
quantification values for the method were found to be 0.2 and 0.7 μg/mL, respectively.
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CHAPTER IV
RESULTS AND DISCUSSION
Polymer screening and in vitro evaluation of polymeric FSSs
A selection of 13 polymers from different chemical classes, all described by their
suppliers or in literature as film formers were evaluated. Each polymer was tested at three
different concentrations, 1%, 2.5% and 5% w/w.
The evaluation criteria employed was based on critical features for practical, accurate and
patient-friendly application of this novel dosage form. The viscosity of the film forming solution
is required to be low to enable an application of the dosage form as a spray, which would ensure
accurate and flexible dosing. As a result, only solutions with low viscosity were considered
successful and were chosen for the next experiment.
Drying time is a very important characteristic of the formed films. Conveniently, the
films should have a drying time ≤ 7 minutes so as to avoid long waiting times for the patient.
Likewise, the prepared films are required to be non-sticky to avoid adhesion to clothes or
any other surfaces. The cosmetic attribute of films is another essential feature important for
patients. Patients prefer films that are transparent and flexible
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Table 5 represents the successful formulations that were clear, with low viscosity and
produced films that were fast drying, with low stickiness and high cosmetic attractiveness.
Table 5: Composition of the positively evaluated formulations
w/w
Polymer

%

Appearance

Viscosity

Drying

Stickiness

time

Film

Cosmetic

formation attractiveness

(min)

Kollidon® 2.5%
30

Clear

5%

Kollidon® 2.5%
90F

Clear

5%

Kollidon® 2.5%
SR

5%

Eudragit

2.5%

RLPO

5%

Eudragit

2.5%

E100

5%

Eudragit

2.5%

EPO

5%

Soluplus

2.5%

Clear

Clear

Clear

Clear

Clear

Low

≤5

Low

7

Low

≤5

Low

5

Low

7

Low

7

Low

≤5

Low

7

Low

5

Low

5

Low

5

Low

7

Low

5

Low

Complete Transparent

Low

Complete Transparent

Low

Complete Transparent

Low

Complete Transparent

Low

Complete Transparent

Low

Complete Transparent

Low

Complete Transparent

As can be deducted from the results, both the nature and the content of the polymer have
a vital impact on the properties of the formed films. The choice of the polymer is important
16

because the polymer has first to be soluble in a volatile skin-tolerant solvent. Polymers that
aren’t sufficiently soluble in volatile solvents will have the problem of prolonged drying time or
lacking the ability to give clear solutions and subsequently homogenous clear films.
Equally important parameter is the polymer content. While increasing the polymer
amount increases the drug loading capacity of the formulation, this has an inverse impact on the
viscosity of the formulation as well as the thickness and cosmetic attributes of the produced film.
More viscous solutions are difficult to dispense and produce films that are thicker, less invisible
and less flexible. For these reasons the type and the amount of the film forming polymer have to
be determined carefully when formulating polymeric film-forming solutions.
Compound light microscopy
Five different concentrations of each drug in each of the selected polymeric solutions
were prepared (1%, 1.5%, 3%, 5% and 10% w/w). The results varied with polymer type and
concentration. Solutions with higher polymer concentrations were able to prevent and stabilize
the drugs against crystallization. However, the anti-nucleating capacity of the drug was limited
by the drug solubility in the polymeric matrix. Accordingly, the solutions that passed the
microscopic evaluation were the ones with the higher polymer concentration and medium drug
loading capacity.
Table 6 shows the composition of the formulations that didn’t show any signs of drug
precipitation and or crystallization at all time points.
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Table 6: Composition of drug loaded FFSs that passed the microscopic evaluation.
Formulation Code

Composition

Formulation A

5% kollidon 30+

3% Diclofenac Na

Formulation B

5% kollidon 90F+

3% Diclofenac Na

Formulation C

5% Soluplus +

3% Diclofenac Na

Formulation D

2.5% kollidon 90F+ 3% ketoprofen

Formulation E

5% kollidon 90F+

Formulation F

5% Eudragit E100 + 3% Ketoprofen

Formulation G

2.5% Eudragit E100+ 3% ketoprofen

Formulation H

2.5% Eudragit EPO+ 3% ketoprofen

3% ketoprofen

Formulation evaluation on pig skin
After loading the formulations with drugs, it’s crucial at this stage to make sure that the
drugs’ incorporation hasn’t led to any changes in the desirable film characteristics. Evaluation
using pig skin provides a better assessment of the films as they are formed on a surface that most
closely resembles the actual wearing conditions. Consequently, full thickness pig skin was used
to evaluate the films drying time, stickiness, cosmetic attractiveness and flexibility.
Film flexibility is a key feature of in situ films produced by FFS. As the solutions are
expected to be used on considerably large surface areas of the skin, it’s very important for the
films to be of sufficiently flexible and elastic. This is required to prevent any fissures or cracks
disrupting the film upon movements of the patient.
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Table 7 represents the composition of the formulations that gave positive results in all the
testing criteria.
Table 7: Composition of FFS that passed the pig skin evaluation experiment.
Formulation Code

Drug (w/w%)

Polymer (w/w%)

A

Diclofenac Na (3%)

Kollidon 30 (5%)

B

Diclofenac Na (3%)

Kollidon 90F (5%)

C

Ketoprofen (3%)

Kollidon 90F (2.5%)

D

Ketoprofen (3%)

Eudragit E100 (5%)

In vitro drug release study
As the principal goal of this work was to formulate FFS capable of producing films that
prolong topical delivery of NSAIDS. An in vitro experiment method was designed using an
artificial membrane. The artificial membrane chosen was Cellulose dialysis membrane, which
has been extensively used to investigate drug release from topical formulations. The membraneformulation interactions were assessed in preliminary work, to make sure that the membrane acts
only as an inert holding not a barrier for drug diffusion once it’s released from the polymeric
matrix. Data, not showing here, from the 24 h soaking of the membrane in formulations with
different drug concentrations showed that the membrane didn’t cause any changes in the amount
of the drug indicating the inertness of the membrane.
Similarly, solubility testing of the ketoprofen and diclofenac Na in PBS revealed that the
solubilities of both drugs are at least 20x the expected amounted of the drugs to permeate. The
solubility of ketoprofen was found to be at least 5 mg/ml and that for diclofenac Na 9 mg/ml.
19

The formulations that adequately satisfied the criteria about drying time, outward
stickiness, cosmetic acceptability and film flexibility in pig skin testing were evaluated for their
diffusion ability and release characteristics.
Diclofenac release form kollidon 90F and kollidon 30 was investigated. The cumulated
drug amount released (µg) per unit surface area was plotted as a function of time. Although both
films sustained diclofenac release for up to 24 h, the release of diclofenac was higher from
kollidon 90F corresponding to 105 µg/cm² (almost 50% of drug loading) reaching a maximum
release rate at three h with a steady state release rate reached after 6 h. The differences in the
release profiles between the two polymers are due to differences in the polymer-drug
interactions. Such interactions determine the diffusivity of the drug in the polymeric matrix, the
ability of the polymer to prevent crystallization of the drug and the extent to which the polymer
is able to support the supersaturated state after solvent evaporation.
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3%Diclofenac in Kollidon 30

3%Diclofenac in Kollidon 90 F
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Figure 1: In vitro release profile of Diclofenac Na from polymeric film-forming
solutions. (mean of n=3± S.D)

The drug transport data across cellulose dialysis membrane of 3% ketoprofen in kollidon
90F and 3% ketoprofen in Eudragit are shown in figure 2. As evident from the figure, the release
of ketoprofen form Eudragit E100 was higher than kollidon 90F. The total amount of ketoprofen
released was 70 µg/cm² (almost 35% of the loading dose) reaching a maximum release at 2 h
after which a relatively constant drug release was maintained.
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Figure 2: In vitro release profile of Ketoprofen from polymeric film-forming
solutions. (mean ± standard deviation; n=3)

Based on the presented results 3% Diclofenac in kollidon 90F and 3% Ketoprofen in
Eudragit E100 were chosen for further optimization and permeation testing using dermatomed
human cadaver skin.
Ex vivo permeation study
To further optimize the performance of the two selected formulations, menthol was added
at a concentration of 0.08% w/w. Incorporation of penetration enhancer is one of the most common
methodologies used to improve drug permeation and partitioning into the skin. Key features that
play an important role when selecting a penetration enhancer are; safety and performance.
Penetration enhancers shouldn’t cause any irritation or allergizing effect to the skin; also, they
should have a quick, predictable and reversible effect on the stratum corneum (SC).
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Menthol a monocyclic terpenoid alcohol has as a long history of use in topical products,
either for its cooling and refreshing sensation or to enhance the diffusivity and partitioning of both
hydrophilic and lipophilic drugs

7-10

. Menthol acts on the intercellular lipids impeded within the

stratum corneum corneocyte cells. It exerts its effect via disrupting the highly ordered structure of
the lipid bilayer, by increasing the fluidity of the SC lipids11. Additionally, menthol is included in
the list of generally recognized as safe agent list established by the US Food and Drug
Administration. Therefore, menthol was included in the formulations that gave better results in the
in vitro release testing.
Table 8: Final composition of the optimized formulation (w/w%)
Formulation

Diclofenac in Kollidon

Ketoprofen in Eudragit

90F

E100

Drug %

3

3

Menthol %

0.08

0.085

Polymer %

5

5

Ethanol %

91.92

91.92

The permeation profile of ketoprofen from Eudragit E100 and 2% ethanolic solution were
investigated. Statistically, the difference in the steady-state flux of ketoprofen from the test
formulation and the control is nonsignificant. (p ≥ 0.05). The fact that the test formulation gave
comparable results to the saturated ethanolic solution indicates that the polymer has a major
enhancing effect on the drug flux.
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Figure 3: Ex vivo permeation profile of Ketoprofen from FFS and polymer-free
saturated ethanolic solution (mean of n=6± S.D)

As for diclofenac sodium permeation study, the results of the permeation study for both
test formulation and marketed gel Voltaren® didn't result in a good flux profile similar to what
we saw with ketoprofen. Accordingly, we are only showing the cumulative amount of diclofenac
sodium retained in the skin.
Drugs quantification within skin layers
Figure 4 and 5 show the recovered amount of ketoprofen and diclofenac sodium
respectively, represented in µg/mg weight of dermatomed skin. In the case of ketoprofen, the 2%
w/w ethanolic solution of ketoprofen showed a higher amount of retained drug than the
polymeric FFS, an observation that requires more investigation.
Even though permeation studies of diclofenac sodium didn’t result in a good flux profile,
we were able to quantify the amount of drug retained within the skin at the end of the permeation
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study. Voltaren® gel resulted in a higher amount of the active retained within the skin compared
to diclofenac sodium FFS.

Amount of ketoprofen present in
the tisssue (µg/mg)

8
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4
3
2
1
0
3% Ketoprofen in Eudraget E 100

2% Ethanolic solution of ketoprofen

Figure 4: Recovered amount of ketoprofen in µg/mg of dermatomed skin from
ketoprofen FFS and a control solution. (mean of n=6 ± SD)
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in the tisssue (µg/mg)

Amount of diclofenac Na present
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0
3% Diclofenac in Kollidon 90F

Voltaren gel

Figure 5: The Recovered amount of diclofenac sodium in µg/mg of dermatomed skin
from diclofenac sodium FFS and Voltaren® marketed gel. (mean of n=6 ± SD)
Stability study
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Results from these studies are an essential part of drug development process and mandatory
requirement by regulatory authorities. Table 10 shows the drug assay results for the four
formulations that were kept for stability testing at 25°C /40% RH and 40°C /75% RH for 3 months.
According to the obtained results, all formulations passed stability testing at 3 months, they
all gave results within the acceptable limits.

Table 9: 3-month stability testing drug Assay% results (n=3, mean ± SD)
Formulation

Fresh solutions

3% ketoprofen in 101.5 ± 0.65

25°C /40% RH

40°C /75% RH

101.16 ± 0.47

101.90 ± 0.18

97.20 ± 0.51

97.37 ± 0.68

97.48 ± 0.60

102.29 ± 0.42

99.59 ± 0.70

99.20 ± 0.44

Eudragit E100
3% ketoprofen in 102.35 ± 0.34
Kollidon 90F
3% diclofenac Na in 102.21 ± 0.62
Kollidon 30
3% diclofenac Na in 103.08 ± 0.05
Kollidon 90F
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HPLC Analysis
Ketoprofen: table 11 shows the HPLC results of ketoprofen standards in methanol. The
limit of quantification (LOQ) was found to be 0.0625 μg/mL. Lower concentrations than 0.0625
μg/mL of ketoprofen in methanol were detectable but not quantified precisely. Figure 6 shows
ketoprofen calibration curve that was found to be linear in the range 0.0625 μg/mL to 100 μg/mL
with a correlation coefficient (R2 ) of 1.

Table 10: HPLC calculated areas for different ketoprofen standards in methanol
Concentration

Area

(µg/ml)
100

3281097

50

1636094

10

344777

5

166785

2.5

83156

1

32974

0.5

15877

0.25

7826

0.125

4169

0.0625

1549
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Figure 6: Ketoprofen standard calibration curve.

Diclofenac sodium: table 12 shows the HPLC results of diclofenac sodium standards in
methanol. The limit of quantification (LOQ) was found to be 0.125 μg/mL. Lower concentrations
than 0.125 μg/mL of ketoprofen in methanol were detectable but not quantified precisely. Figure
7 shows diclofenac sodium calibration curve that was found to be linear in the range 0.125 μg/mL
to 50 μg/mL with a correlation coefficient (R2 ) of 0.999.
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Table 11: HPLC calculated areas for different ketoprofen standards in methanol
Concentration

Area

(µg/ml)
50

810039

10

162273

5

79609

2.5

37629

1

14757

0.5

15863

0.25

3459

0.125

2977

900000
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y = 16185x + 472.57
R² = 0.9999

700000

Area

600000
500000
400000
300000
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0

0
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20
30
40
Concentration (µg/ml)

50

Figure 7: Diclofenac sodium standard calibration curve
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CHAPTER V
CONCLUSION
Film forming solutions were formulated with polymers from different chemical
groups such as acrylates (Eudragit_ RL PO, Eudragit_ E100, Eudragit_ EPO) Kollidon (
30, 90F, SR), Soluplus, Carbopol, and PVA. These formulations contained one of the
polymers, a volatile solvent, and the drug substance. The developed rating system, even
though based on qualitative test methods, provided a good basis for the evaluation of the
developed formulations comprising key features for patients that would ensure higher
patient satisfaction and compliance. The positively evaluated preparations resulting from
the formulation experiments provided the basis for the development of film-forming
polymeric solutions for ketoprofen and diclofenac Na as a novel dosage form for topical
delivery of non-steroidal anti-inflammatory drugs (NSAIDS).
The focus of this work was to develop and investigate the release potential of FFS
of diclofenac Na and ketoprofen. In the case of ketoprofen, Eudragit E100 was identified
as a potential matrix; producing high-quality films and showing promising release profile
comparable to a saturated ethanolic solution. For diclofenac Na, due to the poor
permeability nature of the drug, we didn’t manage to get a flux profile for neither the
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marketed or our formulation. However, detectable amounts of the drug were found
retained in the skin after applying the formulations for up to 24 hours.
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